Navigation

Great Basin Great Basin Dedicated to developing simple yet powerful point-of-care technology and products
Home

Main Menu

  • Home
  • Products
    • Tests and Panels
    • The System
    • Resources
    • Antimicrobial Stewardship
  • About
    • Careers
  • News
    • Press Releases
    • In the News
Return to Content
You are here: Home › Blog › Seethru Equity Updates GBSN Report Following Latest FDA Clearance

Seethru Equity Updates GBSN Report Following Latest FDA Clearance

Posted on July 18, 2017 in Featured, Investors

Seethru Equity updated their report of Great Basin following the FDA clearance of the company’s Stool Bacterial Pathogens Panel.

View Post
View Link

Share this:

  • LinkedIn
  • Facebook
  • Twitter
  • Google
  • Email
  • More
  • Print
  • Reddit
  • Tumblr
  • Pocket
  • Pinterest
Stool Bacterial Pathogens Panel Receives FDA Clearance; Commercial Rollout Begins Immediately

News and Media

  • News
  • Press Releases
  • In the News
  • Events
  • Popular
  • Latest
  • Tags
  • Great Basin Announces New CEO December 27, 2004
  • Great Basin Closes Round of Funding January 20, 2005
  • Great Basin Licenses Technology from Yale July 28, 2005
  • Great Basin Files for Additional Patents December 1, 2005
  • Great Basin Announces Patent Filing for Innovative Molecular Diagnostics Technology July 3, 2006
  • Seethru Equity Updates GBSN Report Following Latest FDA Clearance July 18, 2017
  • Stool Bacterial Pathogens Panel Receives FDA Clearance; Commercial Rollout Begins Immediately July 13, 2017
  • Investor Presentation July 7, 2017
  • Seethru Equity Issues Update Report on GBSN July 5, 2017
  • Great Basin Provides Business Update June 26, 2017
antimicrobial stewardship convertible note equity offering Great Basin

Archives

© 2019 Great Basin. All Rights Reserved.

site map :: privacy policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.